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Background
The number of patients diagnosed with hereditary hemolytic anemia (HHA) has increased 
since the advent of novel diagnostic techniques that accurately identify this disorder. Here, 
we report data from a survey on the prevalence and characteristics of patients diagnosed 
with HHA in Korea from 2007 to 2011.
Methods
Information on patients diagnosed with HHA in Korea and their clinical and laboratory 
results were collected using a survey questionnaire. Globin gene and red blood cell (RBC) 
enzyme analyses were performed. In addition, we analyzed data collected by pedia-
tricians.
Results
In total, 195 cases of HHA were identified. Etiologies identified for HHA were RBC mem-
branopathies, hemoglobinopathies, and RBC enzymopathies, which accounted for 127 
(64%), 39 (19.9%), and 26 (13.3%) cases, respectively. Of the 39 patients with hemoglobi-
nopathies, 26 were confirmed by globin gene analysis, including 20 patients with β-tha-
lassemia minor, 5 patients with α-thalassemia minor, and 1 patient with unstable hemo-
globin disease.
Conclusion
The number of patients diagnosed with hemoglobinopathies and RBC enzymopathies 
has increased considerably since the previous survey on HHA in Korea, dated from 1997 
to 2006. This is likely the result of improved diagnostic techniques. Nevertheless, there 
is still a need for more sensitive diagnostic tests utilizing flow cytometry and for better 
standardization of test results to improve the accuracy of diagnosis of RBC mem-
branopathies in Korea. Additionally, more accurate assays for the identification of RBC 
enzymopathies are warranted.
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INTRODUCTION
Intrinsic red blood cell (RBC) defects can result from a 
variety of different inherited genetic mutations as well as 
from acquired nutritional deficiencies that affect the struc-
tural proteins of RBCs, globin chain synthesis, and normal 
expression of intracellular enzymes. These disorders are typi-
cally associated with premature RBC destruction and anemia. 
Hereditary spherocytosis is the most common inherited 
hemolytic anemia (HHA). Hereditary spherocytosis is char-
acterized by defects in the cytoskeletal protein, spectrin, 
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Table 1. Annual incidence of disease subtypes.
Year Membranopathy (%)
Hemoglobinopathy 
(%)
Enzymopathy 
(%)
2007   26 (20.5)   7 (17.9)   8 (30.7)
2008   26 (20.5)   4 (10.3)   2 (7.7)
2009   28 (22.1)   7 (17.9)   3 (11.5)
2010   20 (15.6) 11 (28.2)   3 (11.5)
2011   27 (21.3) 10 (25.6) 10 (38.5)
Total 127 39 26
or proteins that contribute to the attachment of spectrin 
to the plasma membrane. This disorder results in osmotically 
fragile spheroidal cells that are selectively trapped in the 
spleen [1].
In the past, hemoglobinopathies were rarely reported in 
Korea. However, the number of patients with HHA is thought 
to have increased in recent years because of the influx of 
people from other South-East Asian populations and because 
of the increased number of interracial marriages in Korea. 
In addition, novel molecular techniques have simplified the 
methods for detecting globin gene mutations.
RBC enzymopathies can be distinguished from hereditary 
spherocytosis using normal osmotic fragility tests with fresh 
erythrocytes or by family genetic analysis. Patients with 
RBC enzymopathy do not have spherocytes on their periph-
eral blood smears and show a partial therapeutic response 
to splenectomy. Currently, there is no simple and convenient 
therapeutic laboratory screening test for glycolytic enzymop-
athy, and the first step in the diagnosis of this disorder 
is through the elimination of easily detected causes of hemol-
ysis, such as spherocytosis and hemoglobinopathies [2].
A standard diagnostic approach for the accurate diagnosis 
of HHA is warranted since 2 nationwide epidemiologic and 
clinical studies in Korea, conducted from 1981 to 1990 [3] 
and from 1997 to 2006 [4], respectively, showed an increase 
in the prevalence of hemoglobinopathies and RBC enzymo-
pathies. To address this, a working party for HHA was estab-
lished by the Korean Hematology Association. This working 
party introduced a standard operating procedure for the diag-
nosis of HHA. Here, we report the epidemiologic and clinical 
data of patients who were diagnosed with HHA since the 
introduction of the standard operating procedure recom-
mended by the Korean HHA Working Party of the Korean 
Hematology Association.
MATERIALS AND METHODS
The medical records of patients diagnosed with HHA using 
the standard operating procedure recommended by the 
Korean HHA Working Party of the Korean Hematology 
Association were analyzed. A survey questionnaire, which 
assessed the information of the medical records, was designed 
by the members of the Korean Hematology Association. This 
survey included only patients 15 years of age and younger. 
This study was approved by the Research Ethics Committee 
of Yeungnam University Hospital (IRB No. PCR-07-44).
Evidences of splenomegaly, gallstones, and cholangitis, 
as well as other relevant physical findings, and a family 
history of anemia were determined using the questionnaire. 
Initial laboratory test results included full blood counts with 
RBC indices, blood smear analyses, reticulocyte counts, iron 
studies, bilirubin concentration, Coombs test, haptoglobin, 
lactate dehydrogenase, and hemoglobin electrophoresis. If 
RBC membranopathy was suspected, the next diagnostic step 
was an osmotic fragility test at room temperature or after 
incubation of the blood sample, followed by an autohemolysis 
test. RBC membrane protein analysis using sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
further used as a diagnostic method in patients for whom 
diagnosis was not definite or if the treating physician chose 
to include this analysis in the diagnostic work-up. Tests 
to establish a diagnosis of thalassemia included Heinz body 
and hemoglobin (Hb) H and Hb F analyses, as well as glycerol 
lysis, heat instability, and isopropanol precipitation tests. 
Direct sequencing and deletion analysis (multiple liga-
tion-dependent probe amplification, MLPA) of the globin 
gene were then performed to ascertain the presence of a 
globin gene mutation [5]. A quantitative assay of the activity 
of RBC enzyme was carried out at a single central laboratory.
Statistical analysis
Data analyses were performed using SPSS version 13. 
Differences between subgroups were assessed using the 2-sid-
ed log-rank test. Differences between means in the different 
subgroups were analyzed using 1-way analysis of variance 
(ANOVA). The Kruskal-Wallis non-parametric test was used 
to compare values of non-Gaussian variables. The chi-square 
test was used to analyze non-continuous variables between 
groups. 
RESULTS
Patient demographics
From January 2007 to December 2011, 195 patients (121 
boys and 74 girls) diagnosed with HHA were registered in 
this survey. The median age at diagnosis was 32 months 
(range, 0–187 months). The annual incidences of the different 
disorders associated with HHA are shown in Table 1. Serial 
increases in the number of patients diagnosed with RBC 
membranopathy, hemoglobinopathy, and RBC enzymopathy 
were observed; the only exception was the number of patients 
diagnosed with RBC membranopathies in 2010, which was 
lower than that of previous years.
Etiology
The most common cause of HHA was RBC membran-
opathies, which were diagnosed in 127 patients (64.8%). 
A diagnosis of hemoglobinopathy and RBC enzymopathy 
was confirmed in 39 (19.9%) and 26 (13.3%) patients, 
respectively. In 3 patients (1.5%), cause of HHA could not 
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Table 2. Comparison of disease subtypes according to period.
Membranopathy (%) Hemoglobinopathy (%) Enzymopathy (%)
Study period (year) 1997–2006 2007–2011 1997–2006 2007–2011 1997–2006 2007–2011 
Patients number (%) 290 (88.1)      127 (64.8) 14 (4.2)         39 (19.9) 7 (2.1)    26 (13.3)
Family history (%) 129 (44.2) 54/127 (42.5)  8 (60) 13/25 (52)   2 (28.6) 4/17 (23.5)
Table 3. Genetic abnormalities of thalassemia.
N
Beta thalassemia 20
    c.a) 129T＞A, (3'UTR) hetero 1
    c.128T＞C hetero Codon 42 TTT＞TCT (Phe＞Ser) 1
    c.-138C＞A hetero 1
    c.19G＞A hetero Codon 6 GAG＞AAG (Glu＞Lys) HbC 2
    c.20A＞T hetero Codon 6 GAG＞GTG (Glu＞Val) 1
    c.217dupA 1
    c.280_294 dup15 hetero (Codon 93_97dup) 1
    c.2T＞C hetero, Initiation Codon ATG＞ACG (Met＞Thr) 1
    c.2T＞G hetero, Initiation Codon ATG＞AGG (Met＞Arg) 1
    c.315+1G＞A, hetero 2
    c.316-179A＞C, (IVS2) hetero 1
    c2T＞G 1
    c.26G＞A 1
    c.48G＞A hetero Codon 15 TGG＞TGA (Trp＞Stop) 2
    c.52A＞T hetero Codon 17 AAG＞TAG (Lys＞Stop) 1
    c.79G＞A hetero Codon 26 GAG＞AAG (Glu＞Lys) 1
    c.92+5G＞C hetero (IVS1+5) 1
Alpha thalassemia
    - α3.7/ααa) 1
    ATR-16 deletion (--/αα) 1
    --HW/αα 1
    --SEA/ααa) 2
Hb M-Saskatoon 1
Unknowna) 1
Unchecked globin gene mutation 12
a)South Asian Mother.
Table 4. Enzyme deficiencies in RBC enzymopathy.
Enzyme name N
PK 3
G6PD 2
Enolase 2
P5N 1
AK 1
LDH 1
6PGD, G6PD 1
G3PD, GR 2
Enolase, GR 1
Enolase, LDH 1
Enolase, PFK, GR 1
GPI, PFK 1
GPI, PFK, GR 1
PFK, GR 1
P5N, G3PD 1
≥4 enzyme deficiencies 6
Abbreviations: PK, pyruvate kinase; G6PD, glucose-6-phosphate 
dehydrogenase; P5N, pyrimidine 5'-nucleotidase; AK, adenylate 
kinase; LDH, lactate dehydrogenase; AchE, acetylcholinesterase; 
G3PD, glyceraldehyde-3-phosphate dehydrogenase; GPI, glucose 
phosphate isomerase; PFK, phosphofructokinase; GR, glutathione 
reductase; ADA, adenosine deaminase; PGK, phosphoglycerate 
kinase; MPGM, monophosphoglyceromutase; 6PGD, 6-phospho-
gluconic dehydrogenase.
be found. The proportion of patients diagnosed with hemo-
globinopathy or RBC enzymopathy was considerably higher 
as compared to that from the previous survey report, which 
assessed the prevalence of HHA from 1997 to 2006 (Table 
2).
Hemoglobinopathies were the second most common cause 
of HHA. A globin gene mutation was confirmed in 26 pa-
tients, of which α- and β-thalassemias were present in 5 
and 20 patients, respectively, and 1 patient had unstable 
hemoglobin disease. In the remaining 13 patients, a diagnosis 
of hemoglobinopathy was made on the basis of clinical and 
laboratory findings only. Details regarding globin gene muta-
tions are listed in Table 3.
In addition, 26 patients were diagnosed with RBC 
enzymopathy. Isolated enzyme deficiencies were found in 
10 patients; these included pyruvate kinase deficiency (3 
patients), glucose 6-phosphate dehydrogenase deficiency (2 
patients), enolase deficiency (2 patients), pyrimidine 5'-nu-
cleotidase deficiency (1 patients), adenylate kinase deficiency 
(1 patient), and lactate dehydrogenase deficiency (1 patient). 
The remaining 16 patients had more than 2 enzymes 
deficiencies. Deficient RBC enzymes in each patient with 
RBC enzymopathy are summarized in Table 4.
Family history
A family history of anemia was assessed in 169 of the 
195 patients. A family history indicative of HHA was estab-
lished in 71 patients (42%). RBC membranopathy, hemoglo-
binopathy, and RBC enzymopathy were confirmed in 54 
of 127 (42.5%), 13 of 25 (52%), and 4 of 17 (23.5%) patients, 
respectively (Table 2).
Symptoms and signs at diagnosis
The following were considered as symptoms and signs 
of RBC membranopathy: anemia, jaundice, splenomegaly, 
hepatomegaly, abdominal distension, and gallstones. The fre-
quency of these symptoms was similar to that reported in 
the 1997–2006 survey [4]. The symptoms and signs of patients 
with hemoglobinopathies were asymptomatic, anemia, and 
jaundice. Anemia and jaundice were the most common symp-
toms of patients with RBC enzymopathies, occurring in 
71.4% and 42.9% of patients, respectively (Table 5).
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Table 5. Symptoms and signs at diagnosis.
Membranopathy 
(%)
Hemoglobinopathy 
(%)
Enzymopathy 
(%)
Jaundice 45.7 6.4 42.9
Skin pallor 39.8 21.3 71.4
Splenomegaly 27.1 12.8 14.3
Hepatomegaly 13.5 0 28.5
Gallstone 3.4 0 14.3
Others 9.3 6.4 14.3
Asymptomatic 0.8 53.2 0
Table 6. Laboratory findings at diagnosis.
Membranopathy Hemoglobinopathy Enzymopathy P
Hemoglobin (g/dL) 9.16±2.8 10.4±2.3   7.8±2.0 0.016
MCV (fL) 81.8±11.6 74.3±17.4 87.7±12.4 0.005
MCH (pg) 29.3±5.6 24.0±6.6 28.8±3.9 0.001
Corrected reticulocyte (%)   5.8±5.3   1.8±1.4   4.7±4.0 0.006
Total bilirubin (mg/dL)   4.7±5.6   7.2±10.1   3.0±1.7 0.139
LDH (IU/L)  583±409  506±463  921±697 0.028
Haptoglobin (mg/dL) 19.8±47.4  135±93.1    16±21.7 0.000
Hemoglobin A2 (%)   1.9±0.7   4.6±7.1   2.4±0.6 0.32
Hemoglobin F (%) 13.6±20 17.8±22   7.5±19 0.58
Table 7. Characteristics of patients with hereditary membranopathy according to severity.
Mild (＞12 g/dL) Moderate (8.1–12 g/dL) Severe (≤8 g/dL) P
Patient number (%)   24 (19.5)   52 (42.3)   47 (38.2)
Male/Female   15/9   31/21   25/22 0.706
Mean age at diagnosis (mo)   86   38   48 0.071
Diagnosis less than 1 mo.     6 (25)   10 (19.2)     5 (10.6) 0.11
Positive family history   15 (62.5)   23 (44.2)   17 (36.2) 0.107
Cholelithiasis     1     2     2 0.97
Splenomegaly     1   15   15 0.02
Mean hemoglobin (g/dL)   13.2     9.9     6.3 0.000
Mean MCV (fL)   83.5   81.6   81.3 0.745
Mean MCH (pg)   32.2   29.3   27.9 0.009
Mean corrected reticulocyte (%)     7.5     5.9     4.9 0.206
Mean bilirubin (mg/dL)     7.3     5.7     2.3 0.001
Mean LDH (IU/L) 446 565 666 0.184
Mean haptoglobin (mg/dL)   10.4   22.7   19.8 0.767
Transfusion     3     7   25 0.00
Splenectomy     3     0   12 0.02
Laboratory findings
Laboratory findings for each disease subtype at the time 
of diagnosis are shown in Table 6. Briefly, hemoglobin con-
centration was lowest in patients with RBC enzymopathies 
(7.8 g/dL, P=0.016). Mean corpuscular volume and mean 
corpuscular hemoglobin concentration were lowest in pa-
tients with hemoglobinopathies (MCV 74.3 fL; P=0.005 and 
MCH 24.0 pg, P=0.001, respectively).
We classified 123 of the 127 patients with RBC mem-
branopathies into subgroups of disease severity (Table 7). 
The 4 remaining patients were excluded because of missing 
laboratory findings. Hemoglobin concentration of more than 
12 g/dL was defined as “mild”; 8.1–12 g/dL as “moderate”; 
and ≤8 g/dL as “severe.” Thirty-eight percent of patients 
were classified as having a severe RBC membranopathy. 
There were no differences in age, gender ratio, family history, 
and frequency of cholelithiasis between subgroups. The fre-
quency of splenomegaly was significantly higher among pa-
tients in the “moderate” and “severe” subgroups than in 
the “mild” subgroup (P=0.02). The total bilirubin concen-
tration was highest in the “mild” subgroup (P=0.001). This 
may be related to the fact that more patients were diagnosed 
in the early neonatal period (25%) in this subgroup. The 
frequency of RBC transfusion (P＜0.001) and splenectomy 
(P=0.02) were significantly different between groups.
Osmotic fragility tests were performed in 60 patients, and 
flow cytometric analyses were performed using blood sam-
ples of 8 patients from 1 institution. We did not have osmotic 
fragility data for the remaining 59 patients. The average 
start and end points of the % sodium chloride were 0.56±0.13 
and 0.33±0.12, respectively.
RBC membrane protein analyses were performed by 
SDS-PAGE on the blood samples of 26 patients. Ten of these 
patients had abnormal membrane proteins, and all patients 
had a low ratio of spectrin to band 3 protein.
Most of the patients with β-thalassemia had mild anemia 
(Hb level ≥8 g/dL), except 2 patients who had severe anemia 
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(Hb level ＜8 g/dL). Five patients were diagnosed with α-tha-
lassemia, 3 of which were born to women from Southeast 
Asia. One patient with an ATR-16 deletion (--/αα) also had 
mental retardation and epilepsy, and was therefore consid-
ered as having contiguous gene syndrome (α-thalassemia 
with mental retardation).
The laboratory findings of hemoglobinopathies are shown 
in Table 6.
Treatment
Folate therapy was given to 71 of the 123 (57.7%) patients 
with RBC membranopathy. Splenectomy was performed in 
15 of 123 (12.2%) patients, and the median age at the time 
of splenectomy was 7.8 years (range, 5–17 years). For the 
other disorders, splenectomy was not required. Transfusion 
was required in 28.4% (35/123) of the patients with RBC 
membranopathies, 10% (2/20) of the patients with hemoglo-
binopathies, and 60% (9/15) of the patients with RBC 
enzymopathies.
DISCUSSION
This study surveyed the prevalence of HHA in Korea dur-
ing the period between 2007 and 2011. By comparing our 
findings with the data of a previous study period (1997–2006), 
we noticed 2 clear differences. Firstly, there was a dramatic 
increase in the frequency of hemoglobinopathy diagnoses 
(4.2% for 1997–2006 vs. 19.9% for 2007–2011) and RBC 
enzymopathy (2.1% for 1997–2006 vs. 13.3% for 2007–2011). 
Secondly, there was a relative decrease in the frequency 
of undiagnosed cases (6.6% for 1997–2006 vs. 1.5% for 2007–
2011). In addition, the number of institutes involved in the 
survey decreased from 30 to 25, and enrolled patients were 
limited to those younger than 15 years of age in the current 
study. The previous study spanned 10 years and enrolled 
333 patients, while the period of the present study was 5 
years with 195 enrolled patients. Therefore, relatively more 
patients per year were analyzed in this study.
In the present study, a diagnosis of RBC membranopathy 
(64.8%) was the leading cause of HHA, and a large percentage 
of patients (38%) had severe RBC membranopathy. Approxi-
mately 60–70% of patients were classified in the group with 
moderate severity, followed by mild severity (20–30%), and 
finally sever group (5–10%) [6]. This means that the majority 
of patients in our survey were categorized in the moderate 
to severe severity groups (80%). Therefore, we think it is 
likely that there are a large number of people in the pop-
ulation with undiagnosed HHA with mild severity, suggest-
ing that more attention is needed to identify patients with 
hemolytic anemia.
In 1 institution, flow cytometry-based tests as well as 
osmotic fragility, direct antiglobulin, and eosin 5-maleimide 
(EMA) binding tests were conducted to diagnose hemolytic 
anemia in patients with conflicting results. The data suggests 
that flow cytometry may be an alternative diagnostic tool 
that can provide additional information in the differential 
diagnosis of hemolytic anemia with spherocytosis [7]. The 
British Committee for Standards in Hematology recommends 
screening tests with high predictive value, such as the cry-
ohemolysis or the EMA binding test [8]. The results of os-
motic fragility tests can be affected by elevated reticulocyte 
counts, and the sensitivity is low. There was a report that 
only 66% of non-splenectomized patients with hereditary 
spherocytosis had increased osmotic fragility in addition to 
those with immune-mediated and other hemolytic anemias 
[9].
While almost all patients with hereditary spherocytosis 
can be cured with splenectomy, the decision to conduct 
a splenectomy should be carefully considered, and the risks 
and benefits should be weighed. In our cohort of younger 
patients with HHA, only 12% were splenectomized, and 
the youngest patient who underwent a splenectomy was 
5 years old. The risk of cholelithiasis increases greatly after 
10 years of age, but the risk of post-splenectomy infection 
is very high in infancy and early childhood; thus, the timing 
of splenectomy should be delayed until 6–9 years of age, 
if possible [6]. The indications for splenectomy are “mod-
erately severe” and “severe” hereditary spherocytosis, as well 
as symptomatic hemolytic anemia, growth retardation, skel-
etal deformity, leg ulcers, and extramedullary hematopoietic 
tumors. Laparoscopic splenectomy is the method of choice 
[10, 11]. The early complications of splenectomy, such as 
local infection, bleeding, and pancreatitis as well as serious 
long-term complications, are relatively well known [12, 13]. 
These include postsplenectomy infection with encapsulated 
bacteria, an increased risk of ischemic heart disease, cerebral 
stroke, pulmonary hypertension, and thrombosis in later life. 
Long-term monitoring for late complications of splenectomy 
is warranted.
Genetic analysis of the globin gene is relatively simple 
to perform, and many patients with hemoglobinopathies can 
be diagnosed using this method. Because of the increased 
influx of people from Southeast Asia, we predict that the 
incidence of hemoglobinopathies in Korea may well increase 
in the future, although there is no substantial evidence to 
support this notion. In the future, large-scale screening for 
hemoglobinopathies targeted at second-generation children 
of Southeast Asian parents may be necessary.
Three different types of RBC enzymopathies, namely, glu-
cose 6-phosphate dehydrogenase deficiency, pyruvate kinase 
deficiency, and enolase deficiency, were detected in a pre-
vious study in Korea. Through the present study, additional 
types of RBC enzymopathies were reported, and 16 of the 
26 patients had more than 2 types of RBC enzyme 
deficiencies. Therefore, the results of quantitative assays for 
enzyme activity should be interpreted with caution. Enzyme 
activity should be estimated by assessing only surviving 
RBCs, without contamination of circulating white blood 
cells. Importantly, assays performed on blood samples may 
not accurately reflect in vivo enzymatic activity. Transfusion 
therapy in the months prior to assay analysis may obscure 
the presence of an enzyme defect. Reversible binding is 
influenced by the regulation of glycolysis, and altered binding 
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by mutant forms of various enzymes cannot be assessed by 
conventional assays [2].
One of the limitations of our survey was the lack of data 
from adult patients. We did not include data from adult 
patients in our analysis because we received a limited number 
of completed questionnaires from adults.
In conclusion, our survey confirmed that the number of 
patients diagnosed with a hemoglobinopathy or RBC enzym-
opathy dramatically increased in Korea in the 2007–2011 
period than in the 1997–2006 period. We propose stand-
ardization of the diagnostic method and the report form 
for the osmotic fragility test. We also advocate the in-
troduction of more sensitive diagnostic tests to diagnose 
membranopathies and enzymopathies in patients with 2 or 
more enzyme deficiencies. We would like to emphasize that 
globin gene study should be considered by physicians for 
patients with microcytic anemia showing no evidence of 
iron deficiency.
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